Literature DB >> 32571997

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.

.   

Abstract

Entities:  

Year:  2020        PMID： 32571997      PMCID： PMC7307533          DOI： 10.1136/jitc-2020-000798corr1

Source DB:  PubMed          Journal:  J Immunother Cancer        ISSN： 2051-1426            Impact factor:   13.751


× No keyword cloud information.
  1 in total

1.  Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.

Authors:  Jing Wu; Yang You; Rongyuan Zhuang; Xi Guo; Chenlu Zhang; Qi Zhang; Yuhong Zhou; Qian Li
Journal:  Ann Transl Med       Date:  2022-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.